NANOBIOTIX (EPA:NANO)

PRESS RELEASE

published on 09/30/2025 at 00:30, 4 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Nanobiotix announces updated phase 1 results supporting JNJ-1900 plus anti-PD-1 as a new option in R/M-HNSCC. Promising local and systemic responses presented at ASTRO 2025

NANOBIOTIX Anti-PD-1 JNJ-1900 R/M-HNSCC ASTRO 2025
BRIEF

published on 09/17/2025 at 22:20, 4 months 12 days ago

New Positive Results for NANOBIOTIX in Phase 1 Melanoma Study

Efficiency Melanoma NANOBIOTIX Phase 1 JNJ-1900
PRESS RELEASE

published on 09/17/2025 at 22:15, 4 months 12 days ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Nanobiotix announces new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors as a 2L+ therapy for patients with primary cutaneous melanoma resistant to anti-PD-1. Favorable safety profile and early efficacy signals observed

Melanoma NANOBIOTIX Immune Checkpoint Inhibitors Phase 1 Study JNJ-1900
BRIEF

published on 09/12/2025 at 19:05, 4 months 17 days ago

Nanobiotix Announces Voting Rights and Share Capital Details

Voting Rights Shares Euronext Nasdaq NANOBIOTIX
PRESS RELEASE

published on 09/12/2025 at 19:00, 4 months 17 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix releases voting rights and shares capital details. The company is listed on Euronext Paris and Nasdaq, pioneering biotechnology for treatment advancements

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 09/02/2025 at 22:20, 4 months 27 days ago

Nanobiotix at the HC Wainwright Global Investment Conference

Investors Biotechnology Conference Therapeutics NANOBIOTIX
PRESS RELEASE

published on 09/02/2025 at 22:15, 4 months 27 days ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Nanobiotix to participate in H.C. Wainwright 27th Annual Global Investment Conference with a fireside chat featuring company management. Nanoparticle-based treatments for cancer and major diseases

Fireside Chat NANOBIOTIX H.C. Wainwright Conference Late-stage Biotechnology Nanoparticle-based Treatments
BRIEF

published on 08/27/2025 at 08:05, 5 months 3 days ago

Nanobiotix Announces Voting Rights and Shares Capital Update

Euronext Paris Voting Rights Biotechnology Shares Capital NANOBIOTIX
PRESS RELEASE

published on 08/27/2025 at 08:00, 5 months 3 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix announces voting rights and shares capital details as per French Commercial Code regulations. The late-stage clinical biotech company focuses on disruptive therapies in oncology, bioavailability, and CNS disorders

Voting Rights French Commercial Code Biotechnology Shares Capital NANOBIOTIX
BRIEF

published on 08/11/2025 at 11:34, 5 months 19 days ago

Threshold Crossings by The Goldman Sachs Group, Inc. at Nanobiotix

Actions Financial Market Goldman Sachs Crossing Thresholds NANOBIOTIX

Published on 01/30/2026 at 14:00, 2 hours 15 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 40 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 14 hours ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 15 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 16:00, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:59, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/30/2026 at 15:58, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 01/30/2026 at 15:57, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/30/2026 at 15:56, 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

View all EQS

Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 22 hours 15 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 22 hours 35 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News